4-hydroxyprogesterone | 650-66-8

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 4-hydroxyprogesterone
• 英文别名: 4-Hydroxy-progesterone；4-Hydroxy-progesteron；4-Hydroxypregn-4-ene-3,20-dione；(8S,9S,10R,13S,14S,17S)-17-acetyl-4-hydroxy-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one
• CAS: 650-66-8
• 化学式: C₂₁H₃₀O₃
• 分子量: 330.467
• InChiKey: DXNJBNPIVVOILB-QCGOMIHKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  24
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.81
• 拓扑面积：
  54.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-hydroxyprogesterone 在 吡啶 、 palladium diacetate 、 三乙胺 、 三苯基膦 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 3.5h， 生成 Pregn-4-ene-3,20-dione, 4-(2-phenylethenyl)-
  参考文献：
  名称：

  Haase-Held, Margret; Hatzis. Maria; Mann, John, Journal of the Chemical Society. Perkin transactions I, 1993, # 23, p. 2907 - 2912

  摘要：

  DOI：
• 作为产物：
  描述：

  4,5-epoxypregnan-3,20-dione 在 甲酸 作用下， 以40%的产率得到4-hydroxyprogesterone
  参考文献：
  名称：

  Haase-Held, Margret; Hatzis, Maria; Mann, John, Journal of the Chemical Society. Perkin transactions I, 1992, # 22, p. 2999 - 3000

  摘要：

  DOI：

文献信息

• C-19 STEROIDS FOR COSMETIC AND FURTHER USES
  申请人：WINDISCH Martin

  公开号：US20100256102A1

  公开（公告）日：2010-10-07

  The present invention relates to novel uses of C-19 steroid compounds, in particular C-19 steroids having an androsten-17-(OR 4 )-3-one structure for cosmetic and further uses, wherein R 4 is hydrogen or an unsubstituted or substituted alkyl, aryl, acyl or any group leading to hydroxyl upon biological metabolization or chemical deprotection. The present invention particularly relates to selected C-19 steroids displaying properties of high binding affinity to androgen receptor to block dihydrotestosterone from binding, while at the same time providing anabolic effects, which is useful for certain applications, particularly for influencing or controlling problems of the skin and its skin-associated body structures like cellulite, wrinkles, adipose fat tissues, hair follikles or hair growth; for influencing or controlling gland function and activity such as the sebaceous gland and other glands affecting the skin and/or perspiration. The present invention also describes a composition comprising a combination of such a compound and dimethyl isosorbide.

  本发明涉及C-19类固醇化合物的新用途，特别是具有雄甾-17-(OR4)-3-酮结构的C-19类固醇用于化妆品和其他用途，其中R4是氢或未取代或取代的烷基，芳基，酰基或任何在生物代谢或化学去保护后导致羟基的基团。本发明特别涉及选择的C-19类固醇，其具有高结合亲和力，可阻止二氢睾酮结合，同时提供肌肉增长效果，这对于某些应用特别有用，特别是用于影响或控制皮肤及其皮肤相关结构的问题，如脂肪团、皱纹、脂肪组织、毛发囊或毛发生长；用于影响或控制腺体功能和活动，如皮脂腺和其他影响皮肤和/或出汗的腺体。本发明还描述了一种组合了这种化合物和二甲基异山梨醇的组合物。
• C-19 steroids for cosmetic and further uses
  申请人：ErlaCos GmbH

  公开号：EP2060261A1

  公开（公告）日：2009-05-20

  The present invention relates to novel uses of C-19 steroid compounds, in particular C-19 steroids having an androsten-17-(OR4)-3-one structure for cosmetic and further uses, wherein R4 is hydrogen or an unsubstituted or substituted alkyl, aryl, acyl or any group leading to hydroxyl upon biological metabolization or chemical deprotection. The present invention particularly relates to selected C-19 steroids displaying properties of high binding affinity to androgen receptor to block dihydotestosterone from binding, while at the same time providing anabolic effects, which is useful for certain applications, particularly for influencing or controlling problems of the skin and its skin-associated body structures like cellulite, wrinkles, adipose fat tissues, hair follikles or hair growth; for influencing or controlling gland function and activity such as the sebaceous gland and other glands affecting the skin and/or perspiration. The present invention also describes a composition comprising a combination of such a compound and dimethyl isosorbide.

  本发明涉及C-19类固醇化合物的新用途，特别是具有雄烯-17-(OR4)-3-酮结构的C-19类固醇用于化妆品和其他用途，其中R4是氢或未取代或取代的烷基、芳基、酰基或经生物代谢或化学脱保护后导致羟基的任何基团。本发明尤其涉及精选的 C-19 类固醇，这些类固醇具有与雄激素受体高结合亲和力的特性，可以阻止二氢睾酮的结合，同时还具有同化作用，可用于某些应用，尤其是影响或控制皮肤及其与皮肤相关的身体结构问题，如脂肪团、皱纹、脂肪组织、毛囊或毛发生长；影响或控制腺体功能和活动，如皮脂腺和其他影响皮肤和/或排汗的腺体。本发明还描述了一种包含此类化合物和二甲基异山梨醇的组合物。
• C-19 steroids for specific therapeutic uses
  申请人：Procima GmbH

  公开号：EP2500062A2

  公开（公告）日：2012-09-19

  The present invention relates to novel uses of C-19 steroid compounds, in particular C-19 steroids having an androsten-17-(OR4)-3-one structure for prophylactic and/or therapeutic uses, wherein R4 is hydrogen or an unsubstituted or substituted alkyl, aryl, acyl or any group leading to hydroxyl upon biological metabolization or chemical deprotection. The present invention particularly relates to selected C-19 steroids displaying properties of high binding affinity to androgen receptor to block dihydotestosterone from binding, while at the same time providing anabolic effects, which is useful for certain applicationsThe therapeutic applications particularly include concepts based on influencing or controlling collagen and related therapeutic aspects, as well as concepts making use of certain disclosed effects the mentioned C-19 steroid compounds based on blocking the androgen receptor (AR) against binding of the natural androgen, dihydrotestosterone (DHT), while primarily circumventing a direct aromatase-inhibiting effect, The present invention also describes a pharmaceutical composition comprising a combination of such a compound and dimethyl isosorbide.

  本发明涉及C-19类固醇化合物的新用途，特别是具有雄烯-17-(OR4)-3-酮结构的C-19类固醇的预防和/或治疗用途，其中R4是氢或未取代或取代的烷基、芳基、酰基或经生物代谢或化学脱保护后导致羟基的任何基团。本发明特别涉及选择的 C-19 类固醇，它与雄激素受体具有高结合亲和力，可以阻止二氢睾酮的结合，同时还具有同化作用，这对于某些应用是有用的，治疗应用特别包括基于影响或控制胶原蛋白和相关治疗方面的概念、本发明还描述了一种药物组合物，该组合物包含此类化合物和二甲基异山梨醇的组合。
• C-19 steroids for treating cellulite
  申请人：Curadis GmbH

  公开号：EP2949361A1

  公开（公告）日：2015-12-02

  The present invention relates to novel uses of C-19 steroid compounds, in particular C-19 steroids having an androsten-17-(OR4)-3-one structure for prophylactic and/or therapeutic uses, wherein R4 is hydrogen or an unsubstituted or substituted alkyl, aryl, acyl or any group leading to hydroxyl upon biological metabolization or chemical deprotection. The present invention particularly relates to selected C-19 steroids displaying properties of high binding affinity to androgen receptor to block dihydotestosterone from binding, while at the same time providing anabolic effects, which is useful for certain applicationsThe therapeutic applications particularly include concepts based on influencing or controlling collagen and related therapeutic aspects, as well as concepts making use of certain disclosed effects the mentioned C-19 steroid compounds based on blocking the androgen receptor (AR) against binding of the natural androgen, dihydrotestosterone (DHT), while primarily circumventing a direct aromatase-inhibiting effect, The present invention also describes a pharmaceutical composition comprising a combination of such a compound and dimethyl isosorbide.

  本发明涉及C-19类固醇化合物的新用途，特别是具有雄烯-17-(OR4)-3-酮结构的C-19类固醇的预防和/或治疗用途，其中R4是氢或未取代或取代的烷基、芳基、酰基或经生物代谢或化学脱保护后导致羟基的任何基团。本发明特别涉及选择的 C-19 类固醇，它与雄激素受体具有高结合亲和力，可以阻止二氢睾酮的结合，同时还具有同化作用，这对于某些应用是有用的，治疗应用特别包括基于影响或控制胶原蛋白和相关治疗方面的概念、本发明还描述了一种药物组合物，该组合物包含此类化合物和二甲基异山梨醇的组合。
• C-19 steroids for cosmetic uses
  申请人：Athenion AG

  公开号：EP2060261B1

  公开（公告）日：2016-03-09